Acknowledging the pivotal role played by the IL-6/STAT3 signaling pathway in tumor progression, efforts to hinder its hyperactivity have involved the exploration of therapeutic strategies such as IL-6 receptor mono-antibodies or STAT3 inhibitors. This evidence concerns the gene IL6 and neoplasm.